Life Sciences Panel Discussion Pfizers approach to External - PowerPoint PPT Presentation

May 07, 2023 •133 likes •213 views

Life Sciences Panel Discussion Pfizers approach to External Innovation and Pharmaceutical Drug Discovery Global 1000 Conference and Showcase 2013 Ron Newbold VP External R&D Innovation Pfizer Worldwide Research March 20, 2014 Pfizers

Life Sciences Panel Discussion Pfizer’s approach to External Innovation and Pharmaceutical Drug Discovery Global 1000 Conference and Showcase 2013 Ron Newbold VP External R&D Innovation Pfizer Worldwide Research March 20, 2014
Pfizer’s Purpose and Mission Our Purpose Innovate to bring therapies to patients that significantly improve their lives Our Mission To Be the Premier, Innovative Biopharmaceutical Company
Comprehensive Effort to Accelerate the R&D Strategy ESI: Engine for Sustainable Innovation 1 2 3 Strategic Externalization Differentiated Greater Focus for competitive advantage Innovation through culture, to strengthen leadership, Precision Medicine our scientific core Quality of Output Probability of Success Speed Cost
Pfizer Major Research Focus Areas R&D Core Areas Neuroscience Oncology Cardio- Inflammation & Vaccines Vascular, Remodelling Metabolic & Endocrine Immunology & Disease Autoimmunity Specialized Areas Pain & Sensory Biosimilars Anti-Bacterials Orphan & Rare Disorders Diseases Anti-Virals Stem Cells (Asia R&D) (Neusentis) 4
Partnering on Next Generation Technologies to Enhance Existing / New Modalities Immunology & Inflammation Cardiovascular & Metabolic Diseases Oncology Vaccines Neuroscience & Pain Rare Diseases
Pfizer Global Seed Fund Develop a pipeline of External Opportunities that External R&D builds with our Research Units – support earlier-stage science U.Va. Spinoff Neoantigenics Announces Collaboration with Pfizer, Investment from CIT to Develop Antibody-based Therapeutics For Cancer January 28, 2014
ERDI - Partnering with Pfizer Worldwide R&D Partnering in the Idea – PoC space provides challenges by • number of global opportunities • limited publicly available information WRD implemented External R&D Innovation (ERDI) team: • Scientific team with dedicated external focus • Centralized hub for external partners and internal research & business leaders in the Idea - POC space (“ One-stop-shopping ”) • Defines External R&D Strategies with RUs and PartnerLines • Executes globally against high priority needs: Identify and prosecute late-breaking science, breakthrough technologies, and quality assets that deliver value to Pfizer www.Pfizer.com/WRDpartnering

Download Presentation

Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend

PANEL 1.2: Nuclear technologies in industry, material sciences and beyond Head, Division of

SESSION 1: IMPROVING QUALITY of LIFE PANEL 1.2: Nuclear technologies in industry, material sciences and beyond Head, Division of Industrial Applications, Centre National de l Energie, des Sciences et des Techniques Nuclaires (CNESTEN)

443 views • 20 slides

Global 1000 Conference and Showcase 2013 GLOBAL 1000 PANEL: LIFE SCIENCES Barbara Araneo, PhD,

Global 1000 Conference and Showcase 2013 GLOBAL 1000 PANEL: LIFE SCIENCES Barbara Araneo, PhD, for Novo Nordisk Diabetes Research Unit 3/23/14 1 Engineering biologics into superior therapies 17 of

440 views • 5 slides

MAM: where we are, where we go panel discussion MAM 9, June. 30, 2016, Budapest, Hungary panel

MAM: where we are, where we go panel discussion MAM 9, June. 30, 2016, Budapest, Hungary panel discussion MAM: where we are, where we go Reseach fields queueing/ruin models: EXP Markov modulated (Kronecker algebra) Markov modulted

266 views • 7 slides

Respect the Claim: A Panel Discussion on Real Life Claims CLM001 Speakers: Paul Boatman

Respect the Claim: A Panel Discussion on Real Life Claims CLM001 Speakers: Paul Boatman Director of Risk Management Prometheus Real Estate Group, Inc. Scott Ritto Vice President, Risk Management Kilroy Realty Corporation

442 views • 33 slides

Athens, 9-5-2019 Mr Costas Michaelides Presentation Panel discussion: The rehabilitation of the

Athens, 9-5-2019 Mr Costas Michaelides Presentation Panel discussion: The rehabilitation of the Greek Banking System as a mean to spur economic growth. The journey we travelled as a country in the last 10 years has been a life changing

223 views • 5 slides

The Massachusetts Life Sciences Center Return on Investment September 29, 2010 0 The

The Massachusetts Life Sciences Center Return on Investment September 29, 2010 0 The Massachusetts Life Sciences Initiative Major objectives State investments in the life sciences Super Cluster: Promote economic development

381 views • 14 slides

ICFHR 2016: Panel Discussion 15:00-16:00 October 26 th , Shenzhen Panel Members: Youbin Chen

ICFHR 2016: Panel Discussion 15:00-16:00 October 26 th , Shenzhen Panel Members: Youbin Chen Gernot Fink Qiang Huo Christopher Kermorvant Lambert Schomaker Michael Blumenstein ( Chair ) 15th International Conference on Frontiers in

723 views • 29 slides

How Can Mathematicians Contribute to Planetary Challenges? Our Panel Amit Apte, International

International Congress of Mathematicians 2018 Discussion Panel Tuesday, August 7 How Can Mathematicians Contribute to Planetary Challenges? Our Panel Amit Apte, International Center for Theoretical Sciences, India Pedro Leite da Silva Dias,

440 views • 23 slides

PANEL 1.2: Nuclear technologies in industry, material sciences and beyond Researcher, Malaysian

SESSION 1: IMPROVING QUALITY of LIFE PANEL 1.2: Nuclear technologies in industry, material sciences and beyond Researcher, Malaysian Nuclear Agency Ilham Mukriz Zainal Abidin is Senior Researcher and Manager at the Malaysian Nuclear Agency s

233 views • 6 slides

& Panel Discussion Information Session October 1, 2014 AGENDA Welcome Make Sure

2014 KGSA Case Competition & Panel Discussion Information Session October 1, 2014 AGENDA Welcome Make Sure to Sign In Committee Overview Details: Case Conference and Panel Discussion Event Date(s) Rules

410 views • 12 slides

5G & IP: Preparing for the next big disruption A Panel Discussion Ed White, Director of

5G & IP: Preparing for the next big disruption A Panel Discussion Ed White, Director of Patent Analytics, Derwent Your Panel Today MIKA ANTTILA, Head of Technical Analysis, Patent Business, NOKIA PAUL CARPENTER, Partner, QIPWORKS Theme One:

112 views • 9 slides

Sparta Twp. Public Schools Community Talk Rewriting the Narrative: A Virtual Panel Discussion on

Sparta Twp. Public Schools Community Talk Rewriting the Narrative: A Virtual Panel Discussion on Racial Trauma June 18, 2020 Virtual Discussion Guidelines Session Recording Mute Feature Chat Box Comments Questions 2 Panel

206 views • 18 slides

Life Sciences Spokane VISION 2030: The Creation of a Health Care and Life Sciences Industry Hub

Life Sciences Spokane VISION 2030: The Creation of a Health Care and Life Sciences Industry Hub October 10, 2018 Marcelo Morales, Founder A4Ventures, VISION 2030 Co-Chair A Little Bit of History MOMENTUM 87 Establish an

651 views • 51 slides

Client Relationship Model Panel Discussion November 8, 2012 CRM Panel Speakers Paul

Client Relationship Model Panel Discussion November 8, 2012 CRM Panel Speakers Paul Strijckers , VP Strategic Initiatives (Broadridge Financial Solutions) David Malone , VP Business Initiatives (RBC Wealth Management Canada)

629 views • 27 slides

SESSION 1: IMPROVING QUALITY of LIFE PANEL 1.2: Nuclear technologies in industry, material

SESSION 1: IMPROVING QUALITY of LIFE PANEL 1.2: Nuclear technologies in industry, material sciences and beyond Special Adviser, Fluid Flow and Environmental Technology, Institute for Energy Technology (IFE) Tor Bjrnstad is Special Adviser at

303 views • 12 slides

Accessing and Manipulating Life-Sciences Ontologies using Web Services Olivier Dameron, Mark A.

Accessing and Manipulating Life-Sciences Ontologies using Web Services Olivier Dameron, Mark A. Musen SMI - Stanford University W3C Workshop on Semantic Web for Life Sciences - oct. 2004 Context: Semantic needs for Life Sciences Huge

571 views • 25 slides

Asynchronous Boolean models of signaling networks Matthew Macauley Department of Mathematical

Asynchronous Boolean models of signaling networks Matthew Macauley Department of Mathematical Sciences Clemson University http://www.math.clemson.edu/~macaule/ Math 4500, Spring 2016 M. Macauley (Clemson) Asynchronous Boolean models of

149 views • 14 slides

Remote Congressional Meeting Training April 16, 2020 www.MEAdvocacyWeek.com About US Emily

Solving M.E. Together Remote Congressional Meeting Training April 16, 2020 www.MEAdvocacyWeek.com About US Emily Taylor Lincoln Clapper Director of Advocacy and Community Relations Director of Sales and Marketing Solve ME/CFS

570 views • 43 slides

HEPATITIS A: PULLING A MOLECULAR RABBIT FROM SAN DIEGOS HAT Tracy Basler June 28, 2019

6/28/2019 1 HEPATITIS A: PULLING A MOLECULAR RABBIT FROM SAN DIEGOS HAT Tracy Basler June 28, 2019 PUBLIC HEALTH SERVICES 1 6/28/2019 SAN DIEGO COUNTY HEPATITIS A OBJECTIVES Participants will be able to: Describe the

254 views • 23 slides

National Viral Hepatitis Roundtable (NVHR) Tina Broder, MSW, MPH Interim Executive Director Our

National Viral Hepatitis Roundtable (NVHR) Tina Broder, MSW, MPH Interim Executive Director Our mission: Working together to eliminate hepatitis B and C in the United States Our vision: A healthier world without hepatitis B and C. Policy

351 views • 5 slides

Autologous Transplant for Multiple Myeloma ? Leona A. Holmberg, MD, PhD Member, FHCRC Professor,

Why Do We Recommend Additional Therapy After Autologous Transplant for Multiple Myeloma ? Leona A. Holmberg, MD, PhD Member, FHCRC Professor, UWA Disclosures Discussion of multiple off label use of FDA approved drugs Research funding

467 views • 28 slides

UK Cell Salvage Action Group UK Cell Salvage Action Group The UK Cell Salvage Action Group is a

UK Cell Salvage Action Group UK Cell Salvage Action Group The UK Cell Salvage Action Group is a subgroup of NHS Blood and Transplant Appropriate Use of Blood Group. It is made up of cell salvage experts from the UK. Aims Support the wider

410 views • 9 slides

Epidemiology: Epidemiology: The times, they are a changing.. Kieren A. Marr MD Director,

Epidemiology: Epidemiology: The times, they are a changing.. Kieren A. Marr MD Director, Transplant and Oncology ID Johns Hopkins University School of Medicine Johns Hopkins University School of Medicine Historic Observations: 1990 -

322 views • 21 slides

T regulatory cells: a key predictor of the host response in mesh complications Amanda Artsen,

T regulatory cells: a key predictor of the host response in mesh complications Amanda Artsen, Rui Liang, Leslie Meyn, Steve Abramowitch, Pamela Moalli University of Pittsburgh Medical Center, Magee-Womens Research Institute Disclosures

590 views • 9 slides